New Analysis Indicates That Novartis Drug Gilenya Shows Significant Early …
New analysis indicates that Novartis drug Gilenya shows significant early …
Filed under: drug treatment news 2010
Basel, October 12, 2012 – New data will be presented at the 28th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) that reinforce the generally early and sustained efficacy benefit and long-term safety …
Read more on Reuters
With rise in prescription drug use comes greater addiction
Filed under: drug treatment news 2010
That pattern follows statewide and national trends, trends coupled with rising numbers of people seeking treatment for prescription drug addiction. The sales of prescription opioid pain relievers nationwide ballooned between 1999 and 2010. The Centers …
Read more on Times Herald-Record
More drug treatment news 2010 Resources
New Analysis Indicates That Novartis Drug Gilenya Shows Significant Early Effect On Reducing Brain Volume Loss At 6 …
New analysis of two large Phase III studies demonstrates a significant early treatment effect of Gilenya on relapses and MRI outcomes, including brain volume loss, in MS patients Data show generally higher … Read News
Gilenya Shows Significant Early Effect On Lowering Brain Volume Loss At 6 Months
Gilenya Shows Significant Early Effect On Lowering Brain Volume Loss At 6 Months … Read News
PVI_slides_e57 – Continuing Medical Education (CME) Resource …
Doses superior to PBO in primary analysis Significant Safety Summary 1. Cohen JA et al. New Engl J Med. 2010;362:402-415. 2. Kappos L et al. N Engl J Med. 2010;362:387-401. 3. Fingolimod [Gilenya]. Prescribing Information. http://www.pharma.us.novartis 2010. Reveals hyperintense lesions Shows … Read Here